Evidence map›Paper›PMID 40560029›Full record

ArticlePharmacy (Basel, Switzerland)2025

Real-World Experience of L-Glutamine in Sickle Cell Disease: A Retrospective Observational Study.

Shouq Turkistani, Atika AlHarbi, Mansoor Khan, Aeshah AlAzmi, Sultan Almutairi, Naglla Elimam, Sultan Alotaibi

Abstract read
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shouq TurkistaniDepartment of Pharmaceutical Care Clinical Services, Ministry of National Guard Health Affairs (MNGHA), Jeddah 21423, Saudi Arabia.ORCID 0000-0002-6314-8681
Atika AlHarbiDepartment of Pharmaceutical Care Clinical Services, Ministry of National Guard Health Affairs (MNGHA), Jeddah 21423, Saudi Arabia.ORCID 0000-0003-1057-7631
Mansoor KhanDepartment of Pharmaceutical Care Clinical Services, Ministry of National Guard Health Affairs (MNGHA), Jeddah 21423, Saudi Arabia.
Aeshah AlAzmiDepartment of Pharmaceutical Care Clinical Services, Ministry of National Guard Health Affairs (MNGHA), Jeddah 21423, Saudi Arabia.ORCID 0000-0002-2761-7559
Sultan AlmutairiKing Abdullah International Medical Research Center, Jeddah 21423, Saudi Arabia.
Naglla ElimamKing Abdullah International Medical Research Center, Jeddah 21423, Saudi Arabia.
Sultan AlotaibiDepartment of Pharmaceutical Care Clinical Services, Ministry of National Guard Health Affairs (MNGHA), Taif 26573, Saudi Arabia.ORCID 0000-0002-2446-6601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell disease (SCD) affects millions globally, with approximately 0.26% of the Saudi population impacted. Despite standard treatments, patients frequently experience vaso-occlusive crises (VOCs). This retrospective observational study evaluated the real-world effectiveness of L-glutamine (Endari

Indexed as

clinical meaningfulnesscost effectivenessEndarihematologyhydroxyureaL-glutaminereal-world experiencesickle cell disease (SCD)vaso-occlusive crises (VOCs)

Identifiers

PMID40560029
PMCPMC12197130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.